Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal Microbiota Transplantation (University Hospital, Ghent)
- Development stage
- Unknown
- Lead developer
- Ghent University Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Nasoduodenal, Rectal
01
Overview
Fecal Microbiota Transplantation (FMT) is a microbial therapy being evaluated by the University Hospital, Ghent, for the decolonization of Gram-negative multi-drug resistant organisms (MDRO) in hospitalized patients. The therapy involves the transfer of a prepared suspension of fecal matter from a healthy donor (allogenic) or the patient's own pre-colonization sample (autologous) into the gastrointestinal tract. The mechanism of action relies on 'colonization resistance,' where a diverse and healthy microbial community outcompetes resistant pathogens for niches and nutrients, produces inhibitory metabolites (such as short-chain fatty acids and bacteriocins), and modulates the host's mucosal immune system to eliminate the MDROs. This approach aims to provide a treatment option where spontaneous clearance fails, potentially reducing the need for patient isolation and the risk of subsequent infections.
- Other names
- FMTAllogenic FMTAutologous FMT
Beyond the preview
Go deeper on Fecal Microbiota Transplantation (University Hospital, Ghent).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fecal Microbiota Transplantation (University Hospital, Ghent).